Tumor-infiltrating lymphocytes (TILs)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Tumor-infiltrating lymphocytes (TILs), covering 2026-03-05 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC [EARLY_Phase 1]